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Objectives
1. Discuss the epidemiology of HPV 
infections in the United States.
2. Describe the pathophysiology, risk 
factors, signs and symptoms, and 
modes of HPV transmission.
3. Identify the negative health 
consequences associated with HPV.
Objectives
4. Summarize the current 
recommendations for preventing HPV 
infections.
5. Identify the different HPV 
vaccinations available and describe 
the latest recommendations for their 
use.
6. Discuss controversies related to 
HPV infections and vaccinations.
Pre-Test
 Question 1: The most common sexually 
transmitted infections in the United States 
are HPV infections.
 Question 2: An individual can become 
infected with only one strain of HPV at a 
time.
 Question 3: The only type of cancer 
linked to HPV is cervical cancer.
Epidemiology
Epidemiology
Epidemiology
 Cervicovaginal Prevalence of Types 6, 11, 16 and 18 Among 
Women Aged 14–59 Years by Age Group and Time Period
HPV
 Family of >200 non-enveloped, double-stranded DNA 
viruses that target human epithelial cells
 >40 types are sexually transmitted
 >13 types may cause cancer
 Numbered in order of discovery
 Classified into groups based on anatomic areas they affect
HPV
 Individuals may be infected with more than one 
type at a time
 The most common viral infection of the 
reproductive tract
 The most common sexually transmitted infection 
(STI) in the United States
Risk Factors
 Early first sexual intercourse
 Multiple sexual partners
 Tobacco use
 Immunosuppression
Signs and Symptoms
Most HPV infections are asymptomatic 
and resolve spontaneously
 Persistent, untreated high risk 
infections may result in precancerous 
lesions
Modes of Transmission
 Spreads from one person to another 
by skin-to-skin contact
 Sexual intercourse
 Intimate, non-penetrative encounters
Sexually Transmitted HPV
 Two categories:
1. Low risk: Cause skin warts around the 
mouth, throat, genitals/anus as well as 
respiratory papillomatosis
• HPV 6, 11
2. High risk: Cause cancer
• HPV 16, 18
Sexually Transmitted HPV
 Affects 6.2 million 14-44 year olds 
every year
 74% between the ages of 15 and 24
Up to 70% of young women will be 
infected with at least 1 type of HPV 
within the first 5 years of starting 
sexual activity
Complications
 Precancerous lesions may progress 
to different types of cancer
 Cervical
 Anal
 Oropharyngeal
 Vaginal
 Vulvar
 Penile
Complications:
HPV-Associated Cancers
 Based on data from 2008-2012, 38,793
HPV-associated cancers occur in the U.S. 
each year
 ~23,000 among women
 ~16,000 in men
 Cervical cancer is the most common 
among women
 Oropharyngeal cancers are the most 
common among men
Complications:
HPV-Associated Cancers
Complications:
Cervical Cancer
HPV 16 & 18 cause 70% of all cases
 Symptoms
 Fatigue
 Weight loss, loss of appetite
 Back, leg, or pelvic pain
 Single swollen leg
 Vaginal discomfort or odorous discharge
 Irregular, intermenstrual, or abnormal 
vaginal bleeding after sexual intercourse
Treatment
Aimed at genital warts and 
precancerous lesions
 Cryotherapy
 Electrocautery
 Surgical excision
 Topical therapies
Prevention
 Abstinence
 Safe sex practices
Cervical cancer screening
HPV testing for oncogenic types
 Immunizations
Prevention: 
Cervical Cancer Screening
 Females 21-65 years old
 Conventional or liquid-based cytologic
testing (Papanicolaou test) every 3 
years
 Females 30-65 years old
 Co-testing with oncogenic HPV tests 
every 5 years

Prevention: 
Cervical Cancer Screening
 Positive HPV test
 Second HPV test in 1 year and/or
 Test to identify HPV type
Prevention: 
HPV Testing for Oncogenic Types
Detect viral DNA or messenger RNA 
(mRNA)
 Indications
 In conjunction with conventional 
cervical screening in females 30-65 
years old
 To triage abnormal results of 
conventional cervical screening
 As follow-up after treatment of cervical 
precancers
Prevention: 
Screening in Men
No Food and Drug Administration 
(FDA)-approved tests to detect HPV 
in men
No recommended screening methods 
to detect HPV-related cell changes in 
men
Prevention: 
Immunizations
Healthy People 2020 
 Goal: Increase immunization rates and 
reduce preventable infectious diseases
 Objectives:
Prevention: 
Immunizations
Prevention: 
Immunizations
Prevention: 
Immunizations
Vaccine type Brand name HPV types covered
Bivalent 
(2vHPV)
Cervarix® 16, 18
Quadrivalent 
(4vHPV)
Gardasil® 6, 11
16, 18
9-valent 
(9vHPV)
Gardasil®9 6, 11
16, 18
31, 33, 45, 52, 58
Gardasil®9 replaced the bivalent and 
quadrivalent HPV vaccines by the 
end of 2016
Prevention: 
Immunizations
Cervarix®
 Initial U.S. approval: 2009
 Manufacturer: GlaxoSmithKline
 FDA indication: Females 9-25 years old
 Dosage & administration:
 Three 0.5 mL intramuscular (IM) injections 
at 0, 1, and 6 months
Gardasil®
 Initial U.S. approval: 2006
 Manufacturer: Merck Sharp & Dohme Corp.
 FDA indications: 
 Females 9-26 years old
 Males 9-26 years old
 Dosage & administration:
 Three 0.5 mL IM injections at 0, 2, and 6 
months
Gardasil®9
 Initial U.S. approval: 2014
 Manufacturer: Merck Sharp & Dohme Corp.
 FDA indications: 
 Females 9-26 years old
 Males 9-26 years old
 Dosage & administration:
 Three 0.5 mL IM injections at 0, 2, and 6 
months
Gardasil®9
 If the 3-dose HPV vaccination series is initiated 
with the bivalent or quadrivalent vaccines, it may 
be continued or completed with Gardasil®9
 If the 3-dose HPV vaccination series has been 
completed with the bivalent or quadrivalent
vaccines, Gardasil®9 is not recommended 
Gardasil®9
 Safety assessed across 7 Phase III trials involving 
>15,000 patients aged 9-26 years
 Common side effects
 Injection site reactions [pain, swelling, 
erythema] (84.8%)
 Headache (13.2%)
 Fever (6.1%)
Prevention: 
Immunizations


Prevention: 
Immunizations
 Routine vaccination:
 Administer a 3-dose series of HPV vaccine on a schedule 
of 0, 1-2, and 6 months to all adolescents aged 11-12 
years. 
 Administer the second dose 1-2 months after the first 
dose (minimum interval of 4 weeks), administer the 
third dose 16 weeks after the second dose (minimum 
interval of 12 weeks) and 24 weeks after the first dose.
 Administer HPV vaccine beginning at age 9 years to 
children and youth with any history of sexual abuse or 
assault who have not initiated or completed the 3-dose 
series.
Prevention: 
Immunizations
 Catch-up vaccination:
 Administer the vaccine series to females 
(2vHPV, 4vHPV, or 9vHPV) and males 
(4vHPV or 9vHPV) at age 13-18 years if 
not previously vaccinated.
 Use recommended routine dosing 
intervals (see previous slide) for vaccine 
series catch-up.
Prevention: 
Immunizations
 For men who have sex with men and 
immunocompromised individuals, use:
 Gardasil®, or 
 Gardasil®9
Prevention:
Immunizations
 Not recommended during pregnancy
 Pregnancy testing is not needed before vaccination
 If a woman is found to be pregnant after initiating the 
vaccination series, no intervention is needed
 The remainder of the 3-dose series should be delayed
until completion or termination of pregnancy
 Ongoing pregnancy registry
Prevention: 
Immunizations Update
 October 20th, 2016:
 CDC and ACIP state that children 9-14 years old may 
receive just 2 doses of the vaccine, 6 months apart.
 The first HPV vaccine dose is routinely recommended at 11-
12 years old. The second dose of the vaccine should be 
given 6-12 months after the first dose.
 Teens and young adults who start getting the vaccination at 
ages 15-26 years will continue to need 3 doses. 
 Children and teens ages 9-14 who already received 2 doses 
of the HPV vaccine less than 6 months apart will require a 
third dose.
 Three doses are recommended for people with weakened 
immune systems aged 9-26 years.
Prevention: 
Immunizations
Immunizations & 
Controversies
 For optimal effectiveness, HPV 
vaccines should be administered 
prior to engaging in sexual activity
Controversies:
Age-related Concerns
 Parents, pro-abstinence activists, 
and social conservatives have 
expressed concern about the 
recommended age for vaccination 
 They argue that it should be up to 
the parents to decide when their 
child gets vaccinated and when to 
discuss the topic of sex
Controversies:
Age-related Concerns
Many believe that the added 
protection from the vaccine will 
prompt adolescents to start engaging 
in sexual activity
Others maintain that it will increase 
the rate of teenage promiscuity
Controversies:
Misconceptions About HPV
 Surveys of parents have found 
several misconceptions that hinder 
vaccine acceptability:
 Failure to recognize HPV as an STI
 Low concern about child’s risk of 
acquiring HPV
 Lack of knowledge about disease 
features and sequelae
Controversies:
Cost of Vaccination
 Each dose of the HPV vaccine costs 
approximately $120-$200
 The total cost for the 3-dose series 
ranges from ~$360-$600
 Administration fees may apply
Controversies:
Cost of Vaccination
Many insurance plans cover the cost 
for all 3 doses
 Vaccines for Children (VFC) Program 
covers HPV vaccination
 Males and females up to 18 years old
Controversies:
Side Effects vs. Adverse Events
 Side effects: Health problems that 
have been shown to be linked to a 
vaccine by scientific studies
 Adverse events: Health problems 
that occur after vaccination that may 
or may not be caused by a vaccine
Controversies:
Serious Adverse Events
 An adverse event is defined by law 
as serious if it is:
 Life threatening, or 
 Results in death, a persistent or 
significant disability or incapacity, 
congenital anomaly or birth defect, 
hospitalization, or prolongation of 
existing hospitalization
Controversies:
Serious Adverse Events
~90 million doses of HPV vaccines 
have been distributed in the U.S. 
from June 2006-March 2016
HPV vaccine Number of doses distributed
Cervarix® 720,000
Gardasil® 79 million
Gardasil®9 10 million
Controversies:
Serious Adverse Events
 In this same time period, the most commonly 
reported symptoms to the Vaccine Adverse Event 
Reporting System (VAERS) database were non-
serious:
 Fainting
 Dizziness
 Headache
 Nausea
 Fever
 Pain, redness, swelling in the arm where the 
vaccine was given
Controversies:
Serious Adverse Events
 2011: Safety assessment of Gardasil® in 9-26 
year old female vaccine recipients between 
August 2006-October 2009
 600,558 doses analyzed
 No statistically significant increased risk for Guillain-
Barré syndrome, stroke, venous thromboembolism, 
appendicitis, seizures, syncope, allergic reactions, or 
anaphylaxis
Controversies:
Damage to Ovaries
 After over a decade of experience, neither the 
CDC nor the FDA have noted patterns between 
HPV vaccination and reproductive problems, 
including
 Premature ovarian failure
 Premature menopause
 Amenorrhea
Controversies:
Vaccine Safety in Pregnancy
 2015: Analysis of VAERS data for pregnant 
women who received Gardasil® from June 2006-
December 2013
 No unexpected patterns in maternal or fetal outcomes
 No safety concerns for pregnant women or their babies
 Gardasil® Pregnancy Registry
 No evidence that the vaccine affects fertility, pregnancy, 
or the baby’s health
Controversies:
Venous Thromboembolism (VTE)
 2014: Analysis of Denmark data from October 
2006-July 2013 
 1,613,798 females aged 10-44 years
 Found no association between Gardasil® and 
VTE during 42 days following vaccination
 Subgroup analyses by age, anticoagulant 
treatment, and oral contraceptive use also 
found no association
Controversies:
Complex Regional Pain Syndrome (CRPS)
 A chronic, painful condition that 
typically affects a single limb 
following an episode of trauma or 
immobilization
Occurs in the general population, 
including adolescents
Controversies:
Postural Orthostatic Tachycardia Syndrome (POTS)
 An abnormally large and sustained increase in 
heart rate when changing from a lying down to 
an upright position
 Relatively common in young adolescents
 Difficult to distinguish from normal physiologic 
responses in this age group
Controversies:
CRPS & POTS
 Review of >80 million females who received the 
vaccine worldwide
 Rates of syndromes in vaccinated females were 
no different from expected rates in their age 
groups
 Review of data provides no evidence of 
association with HPV vaccination
 No evidence justifies leaving individuals 
vulnerable to HPV-related cancers
Controversies:
Guillain-Barré Syndrome (GBS)
 A rare disorder in which a person’s own immune 
system damages nerve cells, causing muscle 
weakness and sometimes paralysis
 Most individuals fully recover
 CDC’s Vaccine Safety Datalink was monitored for 
GBS following administration of >1.4 million 
doses of Gardasil® from August 2006-February 
2012
 No cases of GBS were identified
Controversies: 
Autoimmune Diseases
 2012: Kaiser Permanente Vaccine Study Center 
 2013: Department of Medical Epidemiology and Biostatistics at 
the Karolinska Institute in Sweden and the Statens Serum 
Institute in Denmark
 2014: Institute Pasteur and 113 medical centers in Europe
 2015: HPV vaccine safety data from the United States and Europe
 2015: Cohort study from 2006-2013 in Denmark and Sweden
 No statistically significant differences in the incidence of 
immune thrombocytopenia, autoimmune hemolytic anemia, 
systemic lupus erythematosus, rheumatoid arthritis, juvenile 
rheumatoid arthritis, type 1 diabetes, Hashimoto’s disease, 
Graves’ disease, multiple sclerosis, acute disseminated 
encephalomyelitis, GBS, neuromyelitis optica, optic neuritis, or 
uveitis
Controversies: 
Deaths
 CDC reviews all available information on reports 
of death following vaccines
 It has concluded that there is no evidence 
suggesting that HPV vaccination has resulted in 
death
 There is no pattern of death occurring with 
respect to time after vaccination
 There is no consistent vaccine dose number or 
combination of vaccines given among the 
reports
Post-Test
 Question 1: The most common sexually 
transmitted infections in the United States 
are HPV infections.
Answer: True
 Question 2: An individual can become 
infected with only one strain of HPV at a 
time.
Answer: False
 Question 3: The only type of cancer 
linked to HPV is cervical cancer.
Answer: False
Thank you.
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